Noble Financial Maintains a Buy Rating on Onconova Therapeutics (ONTX)


In a report released today, Ahu Demir from Noble Financial maintained a Buy rating on Onconova Therapeutics (ONTX), with a price target of $12. The company’s shares closed last Monday at $2.34, close to its 52-week low of $1.69.

According to TipRanks.com, Demir is a 3-star analyst with an average return of 2.6% and a 30.0% success rate. Demir covers the Healthcare sector, focusing on stocks such as Dyadic International, Electrocore Llc, and TherapeuticsMD.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Onconova Therapeutics with a $15 average price target.

See today’s analyst top recommended stocks >>

Based on Onconova Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $7.6 million. In comparison, last year the company had a GAAP net loss of $4.48 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts